DBV Technologies Appoints Kevin Trapp as New Chief Commercial Officer
In an exciting announcement, DBV Technologies (NASDAQ: DBVT), a clinical-stage biopharmaceutical company, has appointed industry veteran Kevin Trapp as its Chief Commercial Officer. This strategic move is expected to enhance the company’s mission of developing groundbreaking treatments for food allergies.
Kevin Trapp's Vision and Leadership
Kevin Trapp will directly report to the CEO, Daniel Tasse, and will steer the global commercial strategies behind the Viaskin® Peanut patch. His immediate focus will involve the anticipated submission of the Biologics License Application (BLA) for children aged 4-7 suffering from peanut allergies, slated for early next year. In addition, a second BLA submission for younger children aged 1-3 is projected for later in the year.
Significance of the Appointment
Kevin's return to DBV Technologies is crucial as the company gears up for the VITESSE Phase 3 study results, due later this year. Tasse expressed optimism about Trapp’s role, stating, "Kevin's wealth of experience and knowledge will be critical as we approach the commercialization of our innovations. His commitment to our cause is evident and will guide us in expanding our reach to those in need of effective treatments for food allergies."
Kevin Trapp's Background
With over three decades of experience in the biopharmaceutical sector, Trapp has a proven track record of developing robust commercial strategies. Before returning to DBV, he served as Managing Director at Biotech Value Advisors (BVA), where he provided insights and guidance to several biotech boards. His impressive resume includes pivotal roles at Bristol-Myers Squibb (BMS), where he effectively managed a multi-billion dollar specialty care portfolio and oversaw significant product launches.
Storming Ahead in Food Allergy Treatments
Reflecting on his promotion, Kevin stated, "Returning to DBV Technologies marks the beginning of a pivotal chapter in my career. The commitment to bringing the Viaskin Peanut patch to market fills me with enthusiasm, knowing that it could significantly impact the lives of many families dealing with food allergies." He emphasized the importance of regulatory progress and the urgency of meeting unfulfilled medical needs.
About DBV Technologies
DBV Technologies is dedicated to addressing food allergies through innovative solutions. The company has developed the proprietary VIASKIN® patch technology, designed to offer a non-invasive treatment strategy that works by delivering micro-doses of allergens through the skin. This pioneering approach aims to change how individuals cope with food allergies fundamentally, with an ongoing focus on expanding clinical trials for younger patients.
Company Mission and Overview
Headquartered in Châtillon, France, with operations in North America, DBV Technologies is committed to transforming patient care for those living with food allergies. Their ongoing clinical trials focus on young children, underscoring their dedication to advancing health outcomes in this vulnerable population.
Frequently Asked Questions
Who is Kevin Trapp?
Kevin Trapp is the newly appointed Chief Commercial Officer of DBV Technologies, with extensive experience in the biopharmaceutical industry.
What is the Viaskin Peanut patch?
The Viaskin Peanut patch is an innovative treatment developed by DBV Technologies that aims to help individuals with peanut allergies through epicutaneous immunotherapy.
Why is this appointment important?
Trapp’s leadership is expected to guide DBV Technologies through crucial BLA submissions and commercial strategies, enhancing their reach in the food allergy treatment market.
What does DBV Technologies focus on?
The company focuses on developing treatment options for food allergies using their proprietary patch technology, which re-educates the immune system.
Where is DBV Technologies based?
DBV Technologies is headquartered in Châtillon, France, with additional operations in North America, specifically Warren, NJ.
